HIMS has fallen 68% from its 52-week high of $25.40 to $8.15 as of writing this article. This was caused by a combination of factors including what has been a decimation of sentiment on companies that went public through the SPAC route. This has meant that while the broader market has attained new highs, DeSPACs have trended lower.
Is hims & hers stock a buy after 80% drop?
Telehealth and consumer products company Hims & Hers (HIMS 6.10%) is down more than 80% from its high since going public as a former special purpose acquisition company (SPAC) stock.
Why are short sellers betting on Hims&hers health stock?
Short sellers are betting that Hims & Hers Health will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender.
Is hims & hers a great investment opportunity?
The company now has a market cap of just under $900 million; Hims & Hers doesn't need to become a Fortune 100 company to be a compelling investment opportunity. Nearly doubling revenue last quarter, the company had $320 million in sales over the past four quarters.
Who owns Hims&hers Health Inc (Hims)?
Potential Hims & Hers Health, Inc. ( NYSE:HIMS ) shareholders may wish to note that the Co-Founder, Andrew Dudum... CEO of Hims & Hers Health Inc (30-Year Financial, Insider Trades) Andrew Dudum (insider trades) bought 81,100 shares of HIMS on 12/13/2021 at an average price of $5.93 a share.
Why did HIMS drop?
HIMS has fallen 68% from its 52-week high of $25.40 to $8.15 as of writing this article. This was caused by a combination of factors including what has been a decimation of sentiment on companies that went public through the SPAC route.
Is HIMS a good stock to buy?
Hims & Hers Health has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Is HIMS profitable?
Hims & Hers' stock was up 4.76% to $10.56 Wednesday afternoon. The quarter's gross profit margin was 77% for the second quarter in a row, up from 69% in the first quarter of 2020. The company ended the quarter with 391,000 subscriptions on its platform, up 79% year-over-year.
Is HIMS stock undervalued?
PB vs Industry: HIMS is overvalued based on its Price-To-Book Ratio (2.7x) compared to the US Healthcare industry average (2.2x).
Should I sell my HIMS stock?
Summary. As high-growth names start to make a comeback, investors would do well to consider this healthcare stock. Hims is likely to smash through its 30% revenue growth rate expectations in 2022. At just 5x next year's revenues, for a company that isn't that unprofitable, this stock is worthwhile buying.
Is HIMS publicly traded?
It has been widely reported that Hims last raised $100 million in February 2019 at a post-money valuation of $1 billion. Hims & Hers Health became a publicly listed company on January 19, 2021 after completing a business combination with Oaktree Acquisition, a publicly traded SPAC.
Who owns HIMS company?
Andrew DudumIn 2017, Andrew Dudum founded Hims Inc. with Hilary Coles as part of the Atomic Labs portfolio. Hims initially sold erectile dysfunction treatment sildenafil and hair loss treatments such as minoxidil, biotin vitamins and DHT-blocking shampoo.
How much did hims sell for?
$1.6 billionConsumer-facing digital health startup Hims & Hers on Wednesday completed its merger with special purpose acquisition company Oaktree Acquisition Corp., in a deal valuing the company at $1.6 billion.
Is for hims FDA approved?
Hims doctors may prescribe sertraline to delay ejaculation. However, the company notes that this is an off-label use, which the FDA has not approved. A person can take the medication at the same time every day or as needed 4–8 hours before sexual activity.
How many shares of hims are there?
206.06MHIMS has 206.06 million shares outstanding. The number of shares has increased by 32.41% in one year....Share Statistics.Shares Outstanding206.06MShares Change (YoY)+32.41%Shares Change (QoQ)+0.58%Owned by Insiders (%)21.92%Owned by Institutions (%)45.70%1 more row•May 24, 2022
What sector is hims in?
("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals and provides access to related prescription fulfillment, today reported financial results for the first quarter ending March 31, 2022.